SCHEMBL30159171

SCHEMBL30159171

CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 11/20 0.51
▸ NPY1R P25929 6/20 0.51
▸ NPY2R P49146 4/20 0.51
▸ NPY5R Q15761 4/20 0.51
▸ TFPI P10646 1/20 0.45
▸ KEAP1 Q14145 1/20 0.44
▸ NMT2 O60551 1/20 0.43
▸ NMT1 P30419 1/20 0.43
▸ VIPR1 P32241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159262 0.95 NPY4R (0.48) NPY4RNPY1RNPY2RNPY5RTFPI
SCHEMBL31605449 0.95 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL31605455 0.93 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL30974014 0.92 NPY4R (0.48) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL31097750 0.92 NPY4R (0.52) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL31344449 0.92 NPY4R (0.52) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL30159226 0.92 NPY4R (0.55) NPY4RNPY1RNPY2RNPY5RTFPI
SCHEMBL31605452 0.91 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL31605453 0.91 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RKEAP1
SCHEMBL30531635 0.90 NPY4R (0.56) NPY4RNPY1RNPY2RNPY5RKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS LLC (US) 2026-03-12 — — US disclosed
US-12454771-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS LLC (US) 2025-10-28 — — US disclosed
EP-4556467-A2 METHODS FOR ARRAY SYNTHESIS Vibrant Holdings, LLC (US) 2025-05-21 — — EP disclosed
US-12251674-B2 Substrates, systems, and methods for array synthesis and biomolecular analysis VIBRANT HOLDINGS, LLC (US) 2025-03-18 — — US disclosed
EP-3617219-B1 METHODS FOR ARRAY SYNTHESIS VIBRANT HOLDINGS LLC (US) 2025-02-26 — — EP disclosed
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS, LLC 2023-09-21 — — US disclosed
US-11565231-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS, LLC (US) 2023-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, IAPP, GIPR NPY4R 188/4885NPY1R 60/4885NPY2R 70/4885
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, CALCB, SPPL2B NPY4R 79/4885NPY1R 71/4885NPY2R 50/4885
US-11565231-B2 Substrates, peptide arrays, and methods VIP, IAPP, GIPR NPY4R 188/4885NPY1R 60/4885NPY2R 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback